Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination therapy involves the topical application of Xiangpi Shengji Ointment (XPSJO) in conjunction with a heat-clearing and dampness-drying extract derived from *Coptis chinensis* and *Phellodendron amurense*. Specifically studied for its efficacy in accelerating postoperative wound healing following anal fistula surgery, the treatment works by pharmacologically inhibiting the NF-κB signaling pathway. This inhibition suppresses the production of pro-inflammatory cytokines, including TNF and IL-17, while simultaneously promoting the polarization of macrophages toward the pro-healing M2 phenotype. Additionally, the combination stimulates angiogenesis and tissue remodeling by activating the HIF-1α/VEGF axis, facilitating faster recovery and improved wound closure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiangpi Shengji Ointment + Coptis chinensis-Phellodendron amurense extract.